ArticleFrontiers in neuroscience2025
Differentiation between glioblastoma and solitary brain metastases using perfusion and amide proton transfer weighted MRI.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- Research progress in imaging detection of brain metastases.Frontiers in medicine · 2026Review
- CEST Contrasts Exhibit Significant Regional Variations in the Human Brain at 3 T.NMR in biomedicine · 2025Article
- Late enhancement and wash-out maps for differentiation of glioblastoma and metastases.BMC medical imaging · 2025Article
- Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma.Tomography (Ann Arbor, Mich.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Early diagnostic separation between glioblastoma (GBM) and solitary metastases (MET) is important for patient management but remains challenging when based on imaging only. The objective of this study was to assess whether amide proton transfer weighted (APTw) MRI alone or combined with dynamic susceptibility contrast (DSC) MRI parameters, including cerebral blood volume (CBV), cerebral blood flow (CBF), and leakage parameter (K2) measurements, can differentiate GBM from MET. Methods: APTw MRI and DSC-MRI were performed on 18 patients diagnosed with GBM ( Results: When comparing GBM to MET, nAPT Conclusion: When assessed in Gd-enhanced tumor areas, nAPTw MRI signal intensity alone or combined with DSC-MRI parameters, was an excellent predictor for differentiating GBM and MET. However, the small cohort warrants future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.